Prostate-only, Dose-escalated Radiotherapy Plus Concomitant Androgen Deprivation Therapy in Primary Localized, NCCN High Risk and MMAI Classifier Low or Intermediate-risk Prostate Cancer - a Prospective, Single-arm, Phase II Study
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Goserelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms HypoPro; the HypoPro Trial
- 20 Jan 2025 New trial record